Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 121
Filter
1.
Transplant Proc ; 48(6): 1920-6, 2016.
Article in English | MEDLINE | ID: mdl-27569923

ABSTRACT

BACKGROUND: Smoking is a modifiable risk factor for cardiovascular disease, malignancy, and surgical complications. Transplant center practices toward smokers vary widely and evoke the classic tension between the ethical principles of justice and utility. We sought to assess current smoking policy variation in U.S. kidney, liver, and pancreas transplant centers. METHODS: An online survey was sent to program directors of all United Network for Organ Sharing-approved solid abdominal organ transplant programs regarding their policies toward prior and current tobacco use. RESULTS: Responses were received from 26% of kidney, 31% of liver, and 37% of pancreas transplant centers. Across organ programs, virtually all centers (97% to 100%) reported transplantations for former smokers, whereas 59% of kidney, 62% of liver, and 33% of pancreas programs reported transplantations for current smokers. Organ programs reported similar rates of having smoking cessation programs (74% to 77%) and performing serum cotinine testing (31% to 38%). Smoking was an absolute contraindication to transplantation at 38% of kidney, 15% of liver, and 50% of pancreas programs. Programs with absolute contraindication policies were less likely to perform transplantations in current smokers and more likely to check serum cotinine levels, but no more likely to have smoking cessation programs. CONCLUSIONS: There is variation in tobacco use policies among abdominal organ transplant programs and centers. Balancing equity and justice when deciding which patients to waitlist requires an individualized approach to the tobacco-using patient, consideration of organ-specific factors, tobacco-related disease burden, and overall patient health. Such multifaceted assessments might be favorable to inflexible tobacco use policies.


Subject(s)
Health Policy , Organ Transplantation/statistics & numerical data , Smoking , Tobacco Use Disorder , Adult , Female , Humans , Male , Middle Aged , Risk Factors , Smoking Cessation , Surveys and Questionnaires , Waiting Lists
2.
Transplant Proc ; 42(5): 1643-7, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20620492

ABSTRACT

BACKGROUND AND PURPOSE: The influence of African-American ethnicity on outcomes of kidney transplant recipients subjected to early steroid withdrawal remains controversial. Recent studies that suggest no higher risk among African Americans may be biased by recruitment of relatively small number of African Americans or by patient selection. We compared outcomes of African Americans to non-African Americans in a center in which early steroid withdrawal has become the standard of practice. METHODS: This was a single-center prospective study of 133 consecutive patients receiving primary kidney transplants between January 2006 and December 2008, followed for >or=3 months, and managed with a similar immunosuppression regimen that included induction antibody therapy, tacrolimus, mycophenolate mofetil, and withdrawal of steroids on postoperative day 5. Acute rejection and other outcomes were compared in African-American patients (n = 55) and compared with those of non-African-American patients (n = 78). RESULTS: During the first 12 months after early steroid withdrawal, African-American patients experienced a significantly higher cumulative incidence of acute rejection than non-African Americans (23.6% vs 7.7%; P = .020). Using multivariate logistic regression, ethnicity (odds ratio 3.33; P = .047) and HLA mismatch (odds ratio 1.44; P = .041) were significantly correlated with acute rejection independent of recipient age, gender, historical peak panel reactive antibody level (PRA) or PRA at time of transplant, time on dialysis, or donor source. CONCLUSIONS: African Americans are at increased risk of acute rejection after early steroid withdrawal, particularly when they receive kidneys from poorly matched donors.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Black or African American/statistics & numerical data , Ethnicity/statistics & numerical data , Graft Rejection/epidemiology , Kidney Transplantation/physiology , Adult , Aged , Drug Administration Schedule , Drug Therapy, Combination , HLA Antigens/immunology , Histocompatibility Testing , Humans , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/immunology , Living Donors/statistics & numerical data , Methylprednisolone/administration & dosage , Methylprednisolone/therapeutic use , Middle Aged , Prednisone/administration & dosage , Prednisone/therapeutic use , Substance Withdrawal Syndrome/epidemiology
3.
Clin Nephrol ; 63(5): 408-12, 2005 May.
Article in English | MEDLINE | ID: mdl-15909604

ABSTRACT

Angiosarcoma in the setting of immunosuppressed renal transplant recipients is exceedingly rare. In this report, we describe the occurrence of angiosarcoma arising at an arteriovenous fistula site of a 39-year-old renal transplant recipient that clinically mimicked a thrombosed aneurysm. These tumors are histologically high-grade and clinically aggressive malignancies. They have a predilection for arteriovenous fistula sites. The literature on this uncommon entity is reviewed and possible histogenesis is discussed.


Subject(s)
Arteriovenous Fistula/pathology , Hemangiosarcoma/pathology , Immunocompromised Host , Kidney Transplantation/immunology , Vascular Neoplasms/pathology , Adult , Biopsy, Needle , Disease Progression , Fatal Outcome , Hemangiosarcoma/etiology , Hemangiosarcoma/surgery , Humans , Immunohistochemistry , Kidney Transplantation/adverse effects , Male , Risk Assessment , Vascular Neoplasms/etiology , Vascular Neoplasms/surgery
4.
Surgery ; 130(4): 546-52; discussion 552-3, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11602883

ABSTRACT

BACKGROUND: Beginning in 1984, all pancreas transplantations performed in the state of Ohio have been tracked by the Ohio Solid Organ Transplantation Consortium (OSOTC). In this study the outcomes of these transplantations were compared across 3 eras to determine whether increasing experience has been beneficial. METHODS: Between July 1984 and December 1999, 765 kidney-pancreas (KPTx) and 76 pancreas only (Ptx) transplantations were performed. Outcomes measures for these 841 pancreas transplantations were compared over 3 eras, 1984 to 1989, 1990 to 1994, and 1995 to 1999. RESULTS: One-year patient survivals for KPTx patients were 87%, 92%, and 94% in the 3 eras, respectively. Graft survival at 1 year was also markedly improved between era 1 and era 3, increasing for PTx patients from 21% to 85% and for KPTx patients from 68% to 85%. Average waiting time increased from 132 to 318 days between era 1 and era 3. Conversely, average length of stay in hospital was significantly decreased from 34 to 18 days. The cost of the procedure, as measured by hospital charges, also decreased when compared in 1985 dollars as a technique to control for inflation. CONCLUSIONS: These data suggest that pancreas transplantation in Ohio has become a very successful and cost-effective therapeutic intervention for patients with type I diabetes with or without concomitant end-stage renal failure.


Subject(s)
Pancreas Transplantation , Aged , Female , Graft Survival , Hospital Charges , Humans , Male , Middle Aged , Ohio , Pancreas Transplantation/adverse effects , Pancreas Transplantation/economics , Pancreas Transplantation/mortality , Treatment Outcome
5.
Adv Perit Dial ; 17: 93-7, 2001.
Article in English | MEDLINE | ID: mdl-11510306

ABSTRACT

Abdominal catastrophe, defined as peritonitis from a visceral source, occurs in a significant number of patients treated by peritoneal dialysis. Peritonitis due to visceral injury is difficult to manage and is associated with high morbidity and mortality. Surgical intervention for both diagnosis and repair is definitive. However, no preventive strategy has been identified to date. The experience at University Hospitals of Cleveland and the published experiences of many other centers demonstrate that the risk of this complication has not changed in parallel with the many other improvements in the technique and outcome of peritoneal dialysis. We propose an approach to improve the understanding and outcome of this devastating complication. First, classification of peritonitis by source, not by organism, may lead to a more focused response to each episode of peritonitis. Second, the importance of antibiotic prophylaxis should be re-assessed in defined clinical settings that have a high likelihood of progressing to abdominal catastrophe. Third, optimal antibiotic regimens need to be devised and applied when visceral injury is highly suspected as a cause of peritonitis. Finally, the results of surgical interventions must be carefully studied.


Subject(s)
Peritoneal Dialysis/adverse effects , Peritonitis/etiology , Humans , Peritonitis/classification , Peritonitis/diagnosis , Peritonitis/microbiology , Retrospective Studies , Viscera/injuries
6.
Photodermatol Photoimmunol Photomed ; 17(2): 79-82, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11338406

ABSTRACT

BACKGROUND: Acute renal allograft rejection contributes to patient morbidity. Standard immunosuppressives are only partially effective and have significant side effects. Extracorporeal photopheresis (ECP) has been effective in reversing the acute rejection process. T cell cytokine expression is implicated in rejection and tolerance but actual changes in the cytokine profile of ECP-treated individuals have not been documented. METHODS: ECP was administered to a patient with acute renal allograft rejection resistant to other immunosuppressives. Enzyme-linked immunosorbent spot (ELISPOT) assay was performed to determine the frequency of mitogen-induced cytokine-producing cells before and after ECP. RESULTS: ECP resulted in resolution of rejection; serum creatinine concentration fell from 7.1 to 2.2 mg/dl; ELISPOT revealed a three-fold increase in the frequency of IL-5 producing cells; IFN-gamma:IL-5 ratio shifted from 2.73 pre-treatment to 1.01 post-treatment. CONCLUSION: Effective therapy of acute allograft rejection with ECP alters the peripheral blood cytokine profile towards "type 2" cytokines, suggesting that alteration of T cell cytokine profiles may contribute to the resolution of the process.


Subject(s)
Graft Rejection/therapy , Kidney Transplantation , Photopheresis , Acute Disease , Female , Graft Rejection/immunology , Humans , Interferon-gamma/blood , Interleukin-4/blood , Interleukin-5/blood , Kidney Transplantation/immunology , Middle Aged , Phytohemagglutinins/pharmacology
7.
Surg Endosc ; 15(2): 183-8, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11285964

ABSTRACT

BACKGROUND: Laparoscopic pneumoperitoneum has been shown to decrease glomerular filtration rate (GFR) and urine volume (UV). Endothelin-1 (ET-1), a potent renal vasoconstrictor, has been implicated. The purpose of this study was to determine renal function, ET-1 gene expression, and peptide localization in kidneys subjected to CO2 pneumoperitoneum. METHODS: Experiments were performed in three groups of anesthetized Sprague-Dawley rats in which GFR and UV were measured before, during, and after insufflation. In the first group (n = 8), pneumoperitoneum (10 mmHg) was established for 30 min. The second group (n = 4) underwent a sham operation without pneumoperitoneum. In the final group (n = 4), kidneys were obtained from normal control animals without any prior surgical instrumentation. PreproET-1 (ppET-1) mRNA levels were measured by reverse transcription-polymerase chain reaction (RT-PCR). The ET-1 peptide was localized within kidneys by immunohistochemistry (IHC). RESULTS: Pneumoperitoneum caused a significant (p < 0.05) 87% decrease in GFR and a 79% decrease in UV from baseline, with a return to baseline values after desufflation. RT-PCR showed a significant (p < 0.05) increase in expression of ppET-1 mRNA in the laparoscopic group; it was 3.52 +/- 0.33 densitometric units (DU), as compared to 0.35 +/- 0.06 DU and 0.57 +/- 0.12 DU in the control and sham groups, respectively. IHC showed enhanced expression of the ET-1 peptide in the vascular endothelium and proximal tubular cells of the laparoscopic group compared to the control and sham groups. CONCLUSION: Pneumoperitoneum induces ET-1 gene and peptide upregulation in the kidney. Expression of ET-1 is increased in the renal vasculature and proximal tubular cells. The elevation of ET-1 and its localization may account for some of the renal dysfunction observed during pneumoperitoneum. This suggests that antagonism of ET-1 may be beneficial in patients with renal impairment undergoing prolonged laparoscopic procedures or in protecting allograft function during and after living donor nephrectomy.


Subject(s)
Endothelin-1/genetics , Pneumoperitoneum, Artificial/adverse effects , RNA, Messenger/metabolism , Renal Insufficiency/etiology , Animals , Base Sequence , Kidney Function Tests , Laparoscopy/methods , Male , Models, Animal , Molecular Sequence Data , Pneumoperitoneum, Artificial/methods , Probability , Rats , Rats, Sprague-Dawley , Reference Values , Renal Insufficiency/diagnosis , Renal Insufficiency/physiopathology , Reverse Transcriptase Polymerase Chain Reaction , Risk Assessment , Up-Regulation
8.
Transplantation ; 71(2): 211-6, 2001 Jan 27.
Article in English | MEDLINE | ID: mdl-11213061

ABSTRACT

BACKGROUND: Utilization of organs subjected to ischemia/reperfusion (I/R) injury could expand the donor pool. Endothelin (ET) is implicated in renal I/R injury. Therefore, our study compared the effectiveness of pre- and postischemic administration of the ET receptor antagonist, Tezosentan, in preserving renal function. METHODS: In a rat model, a kidney was subjected to 45 min of ischemia along with a contralateral nephrectomy. After 24 hr of reperfusion, renal function was assessed by serum creatinine (Scr), inulin clearance (glomerular filtration rate; GFR), and histology. ET-1 peptide expression was localized using immunohistochemistry. Three groups were studied: I/R untreated (n=17), I/R pretreated (n=11), and I/R posttreated (n=13) with Tezosentan (15 mg/kg, i.v.). RESULTS: Tezosentan significantly decreased (P<0.05) the rise in Scr from I/R injury (2.0+/-0.4 mg/dl, before and 2.9+/-0.4 mg/dl, after treatment) compared with untreated animals (4.2+/-0.4 mg/dl). GFR was significantly increased (P<0.05) from 0.13+/-0.03 ml/min (untreated animals) to 0.74+/-0.16 and 0.47+/-0.14 ml/min (pre- and posttreated animals). Untreated animals had significant cortical acute tubular necrosis, which was almost completely prevented by pretreatment with Tezosentan and markedly reduced by posttreatment. Increased ET-1 peptide expression was noted in the renal vasculature and in the cortical tubular epithelium of kidneys exposed to I/R. CONCLUSIONS: The purpose of this study was to optimize the function of kidneys exposed to I/R injury. Pretreatment as well as posttreatment with Tezosentan successfully decreased Scr, increased GFR, and maintained renal architecture in kidneys after ischemia. Therefore, ET receptor antagonists may be useful to preserve renal function in the transplantation setting.


Subject(s)
Endothelin Receptor Antagonists , Ischemia/drug therapy , Kidney/blood supply , Kidney/physiology , Pyridines/pharmacology , Tetrazoles/pharmacology , Animals , Endothelin-1/analysis , Glomerular Filtration Rate/drug effects , Immunohistochemistry , Kidney/chemistry , Kidney Tubular Necrosis, Acute/prevention & control , Male , Pyridines/administration & dosage , Rats , Rats, Sprague-Dawley , Regional Blood Flow/drug effects , Reperfusion Injury/prevention & control , Tetrazoles/administration & dosage , Time Factors
9.
Transplantation ; 70(3): 494-6, 2000 Aug 15.
Article in English | MEDLINE | ID: mdl-10949193

ABSTRACT

BACKGROUND: Recent reports suggest that hypertension may be less common after simultaneous pancreas-kidney transplantation than after kidney transplantation alone. However, the mechanisms for this beneficial effect have not been delineated. We hypothesize that lower blood pressures may result from chronic volume depletion in patients with bladder-drained pancreatic allografts. METHODS: We compared the incidence and severity of hypertension 12 months after transplantation in 79 bladder-drained pancreas-kidney recipients and 46 diabetic kidney-only recipients. These two groups were compared with a smaller group of enterically drained pancreas-kidney recipients. Blood pressure was also compared before and after surgical conversion from bladder to enteric drainage in 10 patients. RESULTS: Hypertension was significantly less common and less severe after pancreas-kidney transplantation than after kidney transplantation alone, but the benefit of the pancreas transplant was evident only in bladder-drained patients. Logistic regression analysis of the bladder-drained pancreas-kidney patients confirmed the independent impact of the pancreatic allograft on the presence of hypertension, indicated an independent association with serum creatinine concentration and donor age, but suggested no correlation with recipient age, race, or number of rejection episodes. A comparison of blood pressures before and after pancreatic conversion from bladder to enteric drainage indicated no significant change in the prevalence or severity of hypertension. CONCLUSIONS: We conclude that the beneficial effect of a pancreas transplant on the prevalence and severity of hypertension after simultaneous pancreas-kidney transplantation is limited to bladder-drained patients. Although it is possible that the effect is mediated by chronic volume depletion, the observation that blood pressure does not increase after conversion from bladder to enteric drainage suggests that other factors may be involved.


Subject(s)
Hypertension/etiology , Kidney Transplantation/adverse effects , Kidney Transplantation/methods , Pancreas Transplantation/methods , Adult , Blood Pressure , Drainage/methods , Humans , Kidney Transplantation/physiology , Middle Aged , Pancreas Transplantation/physiology , Risk Factors , Urinary Bladder/surgery
10.
N Engl J Med ; 341(27): 2049-53, 1999 Dec 30.
Article in English | MEDLINE | ID: mdl-10615076

ABSTRACT

BACKGROUND AND METHODS: For many complex surgical procedures there is an association between a low volume of procedures and an increased risk of death for the patients who undergo the procedures. We examined the effect of the volume of procedures at transplantation centers on the risk of death after liver transplantation. We analyzed all liver transplantations performed in the United States between October 1, 1987, and April 30, 1994. Because the results for 1987 to 1991 were largely similar to those from 1992 to 1994, we focused on the more recent period. RESULTS: Between January 1, 1992, and April 30, 1994, 47 centers performed 20 or fewer liver transplantations each per year (total, 837 transplantations) and were designated low-volume centers, and 52 centers performed more than 20 transplantations each per year (total, 6526) and were designated high-volume centers. The one-year mortality rate for the low-volume centers was 25.9 percent, as compared with 20.0 percent for the high-volume centers. Thirteen centers, all of which had low volumes, had one-year mortality rates of more than 40 percent. Low-volume centers that were affiliated with high-volume centers, such as pediatric transplantation programs, had results similar to those of the high-volume centers. The one-year mortality rate at unaffiliated low-volume centers was 28.3 percent, as compared with a rate of 20.1 percent for the group of all high-volume centers plus affiliated low-volume centers (P<0.001). CONCLUSIONS: As a group, liver-transplantation centers in the United States that perform 20 or fewer transplantations per year have mortality rates that are significantly higher than those at centers that perform more than 20 transplantations per year. Information regarding the outcome of liver transplantation at transplantation centers should be made widely available to the public in a timely manner.


Subject(s)
Liver Transplantation/mortality , Liver Transplantation/statistics & numerical data , Surgery Department, Hospital/statistics & numerical data , Hospitals, Special/statistics & numerical data , Humans , Logistic Models , Quality of Health Care , Survival Rate , Treatment Outcome , United States/epidemiology
11.
J Immunol ; 163(4): 2267-75, 1999 Aug 15.
Article in English | MEDLINE | ID: mdl-10438971

ABSTRACT

While matching for MHC Ags improves renal allograft survival, closely matched grafts sometimes fail due to rejection, and poorly matched allografts are often well tolerated by the recipient. The severity of the rejection process may partially depend on the presence of environmentally primed T cells in the recipient that cross-react with donor Ags. To test for the presence of primed, donor-specific T cells in humans before transplantation, we used an enzyme-linked immunospot assay for detection of allospecific cytokines produced by individual human PBLs. We demonstrate that this approach detects cytokine production at single cell resolution and detects production of IFN-gamma only when there is defined immunologic priming, thus representing a measure of primed donor-specific immunity. Because the environmental Ag exposure of the recipient is not a function of the HLA mismatch between donor and potential recipient, the number of HLA mismatches may not correlate with the frequency of pretransplant, donor-specific IFN-gamma-producing PBLs. Studies of donor-specific IFN-gamma-producing lymphocytes in a cohort of patients being evaluated for renal transplantation corroborated this hypothesis. Moreover, for recipients of both living and cadaver renal allografts, the pretransplant frequency of donor-specific memory cells correlated with the posttransplant risk of developing acute rejection episodes. This improved ability to define the strength of the allospecific immune response by enzyme-linked immunospot assay may allow improved pairing of recipients with donors and identification of kidney allograft donor-recipient pairs at high risk for acute rejection, thus permitting targeted interventions aimed at prolonging graft survival.


Subject(s)
Blood Donors , Epitopes/immunology , Graft Rejection/immunology , Immunologic Memory , Interferon-gamma/biosynthesis , Lymphocyte Subsets/immunology , Acute Disease , Cell Line , Cells, Cultured , Cytokines/biosynthesis , Enzyme-Linked Immunosorbent Assay , Female , Histocompatibility Testing , Humans , Isoantigens/immunology , Kidney Transplantation/immunology , Liver Transplantation/immunology , Lymphocyte Count , Lymphocyte Subsets/chemistry , Lymphocyte Subsets/metabolism , Male , Risk Factors , T-Lymphocytes/chemistry , T-Lymphocytes/immunology , T-Lymphocytes/metabolism
12.
J Transpl Coord ; 9(1): 35-9, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10401361

ABSTRACT

The high success rate of HLA-identical sibling transplants and our previous experience with steroid-free immunosuppressive regimens and cyclosporine withdrawal prompted us to evaluate the safety and efficacy of monotherapy with azathioprine in 12 HLA-identical kidney transplant recipients with a serum creatinine concentration less than 176.8 mumol/L, a 1-way stimulatory index less than 2.0 in a post-transplant mixed lymphocyte culture, and a demonstrated tolerance of a minimum azathioprine dose of 1.0 mg/kg per day without leukopenia. Eleven of 12 patients were successfully converted to azathioprine monotherapy without a significant change in serum creatinine concentration for as long as 76 months. Benefits of steroid and cyclosporine withdrawal included a significant reduction in mean systolic and diastolic blood pressure, number of blood pressure medications, total serum cholesterol, and glycohemoglobin in diabetic subjects. Our results suggest that azathioprine monotherapy is safe and effective in a select group of HLA-identical sibling transplants, but these benefits must be carefully balanced against an associated risk of precipitating acute allograft rejection.


Subject(s)
Azathioprine/therapeutic use , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/immunology , Living Donors , Adult , Creatinine/blood , Drug Monitoring , Female , Follow-Up Studies , Histocompatibility Testing , Humans , Male , Middle Aged , Treatment Outcome
13.
J Surg Res ; 85(1): 101-8, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10383845

ABSTRACT

BACKGROUND: Prolonged cold ischemia time (CIT) can lead to posttransplant renal dysfunction; however, the pathophysiology remains unclear. Endothelin (ET), a potent vasoconstrictive peptide, may play a role in this injury. The purpose of this study was to determine if cold ischemia could induce renal ET-1 gene upregulation and to localize ET-1 peptide expression in the hypothermic kidney. MATERIALS AND METHODS: Kidneys from Lewis rats were perfused with Viaspan, harvested, and stored at 4 degrees C for varying periods of CIT: 0, 6, 24, and 48 h. Preproendothelin-1 (ppET-1) gene upregulation was measured using a reverse-transcription polymerase-chain reaction. ET-1 peptide expression was localized using immunohistochemistry. RESULTS: Control kidneys (0 h CIT) had 0. 56 +/- 0.22 DU of ppET-1 mRNA. After 6 h of CIT, a 2.3-fold increase in this level was noted. Following 24 h of CIT, ppET-1 mRNA was significantly upregulated to 1.96 +/- 0.38 DU (P < 0.05). Immunohistochemistry revealed typical vascular ET-1 staining in control kidneys. At 6 h of CIT, a significant increase in the expression of ET-1 was noted in the peritubular capillaries and vasa recta. After 24 h, intense staining for ET-1 was seen in the medullary collecting ducts. After 48 h of CIT, early cellular necrosis was present along with global decreases in ET-1 expression and ppET-1 mRNA levels. CONCLUSIONS: This study demonstrates that 24 h of cold preservation can induce significant upregulation of the renal ET-1 gene and increase expression of the ET-1 peptide localized to both vascular endothelial and tubular epithelial surfaces of the kidney. Consequently, prolonged cold ischemia prior to transplantation may lead to delayed renal function following revascularization via endothelin-induced vasoconstriction and/or tubular impairment.


Subject(s)
Cold Temperature , Cryopreservation , Endothelins/genetics , Gene Expression Regulation/physiology , Ischemia/genetics , Kidney/physiology , Organ Preservation , Animals , Endothelin-1/metabolism , Immunohistochemistry , Male , Protein Precursors/genetics , RNA, Messenger/metabolism , Rats , Rats, Inbred Lew , Reverse Transcriptase Polymerase Chain Reaction , Tissue Distribution/physiology
15.
Kidney Int ; 55(3): 1011-8, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10027938

ABSTRACT

BACKGROUND: Endothelin (ET), a potent vasoconstrictor, is known to play a role in ischemic acute renal failure. Although preproET-1 (ppET-1) mRNA is known to be up-regulated following ischemia/reperfusion injury, it has not been determined which component of the injury (ischemia or reperfusion) leads to initial gene up-regulation. Likewise, although ET-1 peptide expression has been localized in the normal kidney, its expression pattern in the ischemic kidney has not been determined. Therefore, the purpose of this study was twofold: (a) to determine whether ischemia alone or ischemia plus reperfusion is required for the up-regulation of ppET-1 mRNA to occur, and (b) to localize ET-1 peptide expression following ischemia in the rat kidney to clarify better the role of ET in the pathophysiology of ischemia-induced acute renal failure. METHODS: Male Lewis rats underwent clamping of the right renal vascular pedicle for either 30 minutes of ischemia (group 1), 60 minutes of ischemia (group 2), 30 minutes of ischemia followed by 30 minutes of reperfusion (group 3), or 60 minutes of ischemia followed by three hours of reperfusion (group 4). The contralateral kidney acted as a control. ppET-1 mRNA up-regulation and ET-1 peptide expression were examined using the reverse transcription-polymerase chain reaction and immunohistochemistry, respectively. RESULTS: Reverse transcription-polymerase chain reaction yielded a control (nonischemic) value of 0.6 +/- 0.2 densitometric units (DU) of ppET-1 mRNA in the kidney. Group 1 levels (30 min of ischemia alone) were 1.8 +/- 0.4 DU, a threefold increase (P < 0.05). Group 2 levels (60 min of ischemia alone) increased almost six times above baseline, 3.5 +/- 0.2 DU (P < 0.01), whereas both group 3 and group 4 (ischemia plus reperfusion) did not experience any further significant increases in mRNA levels (1.9 +/- 0.4 DU and 2.8 +/- 0.6 DU, respectively) beyond levels in group 1 or 2 animals subjected to similar ischemic periods. ET-1 peptide expression in the ischemic kidneys was significantly increased over controls and was clearly localized to the endothelium of the peritubular capillary network of the kidney. CONCLUSIONS: Initial ET-1 gene up-regulation in the kidney occurs secondary to ischemia, but reperfusion most likely contributes to sustaining this up-regulation. The marked increase of ET-1 in the peritubular capillary network suggests that ET-induced vasoconstriction may have a pathophysiological role in ischemic acute tubular necrosis.


Subject(s)
Endothelin-1/genetics , Endothelin-1/metabolism , Kidney/blood supply , Kidney/injuries , Reperfusion Injury/genetics , Reperfusion Injury/metabolism , Acute Kidney Injury/etiology , Acute Kidney Injury/genetics , Acute Kidney Injury/metabolism , Animals , Base Sequence , Capillaries/metabolism , DNA Primers/genetics , Endothelins/genetics , Endothelium, Vascular/metabolism , Immunohistochemistry , Kidney/metabolism , Kidney Tubular Necrosis, Acute/etiology , Kidney Tubular Necrosis, Acute/genetics , Kidney Tubular Necrosis, Acute/metabolism , Male , Protein Precursors/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Inbred Lew , Reverse Transcriptase Polymerase Chain Reaction , Up-Regulation
16.
Clin Transplant ; 12(6): 575-8, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9850454

ABSTRACT

In an effort to minimize nephrotoxicity resulting from greater exposure to cyclosporine after Sandimmune to Neoral conversion, we compared two conversion regimens using different dosing ratios. Serial serum creatinine concentrations and trough cyclosporine levels were measured in 26 patients converted from Sandimmune to Neoral using a 1:0.8 dosing ratio (Group 1) and compared to those of 26 patients converted using a 1:1 dosing ratio (Group 2). The percentage change in peak serum creatinine concentration after conversion was greater in Group 2. However, at last follow-up, the dose reductions in each group were comparable. Following conversion, patients in Group 1 required fewer dose adjustments and follow-up blood tests. Compared to conversion using a 1:1 dosing ratio, conversion from Sandimmune to Neoral using a 1:0.8 ratio results in comparable dose reductions and less short-term nephrotoxicity, while requiring less frequent laboratory monitoring.


Subject(s)
Cyclosporine/administration & dosage , Kidney Transplantation , Adult , Creatinine/blood , Cyclosporine/pharmacokinetics , Dosage Forms , Female , Humans , Male , Middle Aged
18.
Nephron ; 79(4): 469-71, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9689164

ABSTRACT

A renal transplant patient developed symptomatic hepatitis after withdrawal from corticosteroids. Tests for hepatitis B e antigen and hepatitis B viral DNA were both positive prior to treatment with 1 million units alpha interferon three times weekly for 3 weeks followed by an increase to 3 million units alpha interferon three times weekly for a total of 16 weeks. At the end of treatment, hepatitis had clinically resolved with conversion to a hepatitis B e antibody positive and hepatitis B e antigen and viral DNA negative state. The renal allograft function remained excellent throughout the course of therapy with interferon.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis B virus , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/virology , Interferon-alpha/therapeutic use , Kidney Transplantation , Adult , Female , HLA-DR1 Antigen/analysis , Humans , Interferon alpha-2 , Kidney Failure, Chronic/surgery , Recombinant Proteins , Time Factors
19.
Transplantation ; 65(7): 993-5, 1998 Apr 15.
Article in English | MEDLINE | ID: mdl-9565106

ABSTRACT

Spur cell anemia is an acquired hemolytic anemia, characterized by an increased percentage of abnormally shaped erythrocytes that are known as acanthocytes. The erythrocytes have numerous spicules irregularly distributed over the cell surface. Spur cell anemia has been described to occur in several conditions, including cirrhosis. We present an unusual case of a young patient with hemochromatosis, alcohol abuse, decompensated cirrhosis, and spur cell anemia who had a spontaneous resolution of the spur cell anemia after orthotopic liver transplantation. This finding suggests that the diseased liver may contribute to transformation of the erythrocyte to the spur cell.


Subject(s)
Anemia, Hemolytic/therapy , Liver Transplantation , Adult , Anemia, Hemolytic/blood , Anemia, Hemolytic/complications , Hemochromatosis/blood , Hemochromatosis/chemically induced , Humans , Liver Diseases/blood , Liver Diseases/complications , Male
20.
Surgery ; 122(4): 842-8; discussion 848-9, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9347865

ABSTRACT

BACKGROUND: Since its inception in 1984, the Ohio Solid Organ Transplantation Consortium has tracked liver transplantation outcomes for its five member institutions. Presented herein is a 12-year summary of this data analyzed to determine whether, with increasing experience, outcomes have improved in a cost-effective manner. METHODS: Between July 1984 and June 1996, 1,063 liver transplants were performed in Ohio in 943 patients (772 adults and 171 children), of which 943 were primary and 120 were retransplants (13%). Outcome comparisons were made for three eras: 1984-1988, 1988-1992, and 1992-1996. RESULTS: The percentage of urgent (United Network for Organ Sharing status 1 and 2) transplants has decreased (62% to 41%), whereas that of homebound patients has increased (38% to 59%). Average time on the waiting list has increased from 39 to 165 days, and the average length of stay has decreased from 44 to 27 days. Patient survival at 1-year increased in each era (64%, 80%, and 82%, respectively). Although actual hospital charges have remained relatively constant, they have decreased substantially when compared in 1985 dollars as corrected for inflation. CONCLUSIONS: Patients undergoing liver transplantation in Ohio are now listed earlier in the course of their disease and wait longer for their transplant, but enjoy a better chance of survival, have a shorter hospital stay, and a relatively less expensive operation. These data indicate that with increased experience, the Ohio Solid Organ Transplantation Consortium liver transplantation teams perform liver transplantation in a more cost-effective manner.


Subject(s)
Liver Transplantation/statistics & numerical data , Tissue and Organ Procurement/organization & administration , Adolescent , Adult , Child , Child, Preschool , Costs and Cost Analysis , Humans , Infant , Liver Diseases/classification , Liver Diseases/surgery , Liver Transplantation/economics , Liver Transplantation/mortality , Middle Aged , Ohio , Outcome Assessment, Health Care , Reoperation , Retrospective Studies , Survival Rate , Treatment Outcome , Waiting Lists
SELECTION OF CITATIONS
SEARCH DETAIL
...